Zelluna ASA (OSTO:ULTIO) ROCE %: -43.63% (As of Mar. 2026)


OSTO:ULTIO Zelluna ASA OSTO:ULTIO
28 GF Score
Price kr21.95
! 2 Warning Signs
View Full Analysis

What is Zelluna ASA ROCE %?

Zelluna ASA OSTO:ULTIO 28 ROCE % is -43.63% as of Mar. 2026. GuruFocus rates OSTO:ULTIO with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zelluna ASA's annualized ROCE % for the quarter that ended in Mar. 2026 was -43.63%.

Zelluna ASA  (OSTO:ULTIo) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zelluna ASA ROCE % Related Terms

Zelluna ASA ROCE % Historical Data

* Premium members only.

The historical data trend for Zelluna ASA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelluna ASA ROCE % Chart

Zelluna ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.60 -34.37 -57.02 -55.97 -73.40

Zelluna ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -106.76 -134.89 -200.81 -75.96 -43.63
OSTO:ULTIO
28GF Score
Zelluna ASA OSTO:ULTIO
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelluna ASA ROCE % Calculation

Zelluna ASA's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-140.613/( ( (113.529 - 30.81) + (308.07 - 7.65) )/ 2 )
=-140.613/( (82.719+300.42)/ 2 )
=-140.613/191.5695
=-73.40 %

Zelluna ASA's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-80.16/( ( (308.07 - 7.65) + (75.838 - 8.802) )/ 2 )
=-80.16/( ( 300.42 + 67.036 )/ 2 )
=-80.16/183.728
=-43.63 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -43.63% mean?
Zelluna ASA (OSTO:ULTIO) has a ROCE % of -43.63% as of Mar. 2026.
Is Zelluna ASA's ROCE % too high?
Zelluna ASA's current ROCE % is -43.63%. Overall, Zelluna ASA has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Zelluna ASA's ROCE % compare to VRTX and REGN?
Zelluna ASA's ROCE % of -43.63% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Zelluna ASA's current ROCE % is -43.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelluna ASA stock overvalued right now?
Zelluna ASA (OSTO:ULTIO) has a current ROCE % of -43.63%. The current ROCE % is -43.63%. Zelluna ASA's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Zelluna ASA (OSTO:ULTIO), the current ROCE % is -43.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelluna ASA Business Description

Other Exchanges ZLNA:Norway7UM0:Germany
Address Ullernchausseen 64, Oslo Cancer Cluster Innovation Park, Oslo, NOR, 0379
Zelluna ASA is a biotechnology company established to eliminate solid cancers by unleashing the powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). Its TCR-NK products are composed of healthy donor-derived NK cells that are genetically engineered to express a tumour-specific TCR that enable the TCR-NK cells to identify and eliminate cancer cells in the body of the patient. Its programme ZI-MA4-1, the first MAGE-A4-targeting TCR-NK therapy for solid tumours with high unmet medical need. Its other programmes include ZI-KL1-1, and ZI-PR-1.
28GF Score

Get the complete analysis for OSTO:ULTIO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr21.95
Price